SCHEMBL432399

SCHEMBL432399

C[C@H](N)C(=O)OC(=O)[C@@H](N)CCC(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PMP22 Q01453 2/20 0.50
ALOX15 P16050 1/20 0.50
BLM P54132 1/20 0.50
KMT2A Q03164 1/20 0.50
DPP4 P27487 2/20 0.45
DPP8 Q6V1X1 2/20 0.45
DPP9 Q86TI2 2/20 0.45
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35
GABRP O00591 2/20 0.33
GABRD O14764 2/20 0.33
GABRA1 P14867 2/20 0.33
GABRB1 P18505 2/20 0.33
GABRG2 P18507 2/20 0.33
GABRB3 P28472 2/20 0.33
GABRA5 P31644 2/20 0.33
GABRA3 P34903 2/20 0.33
GABRA2 P47869 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28313344 0.90 ALOX15 (0.60) PMP22ALOX15BLMKMT2ADPP4
SCHEMBL711607 0.90 ALOX15 (0.60) PMP22ALOX15BLMKMT2ADPP4
SCHEMBL508161 0.87 ALOX15 (0.48) PMP22ALOX15BLMKMT2ADPP4
SCHEMBL1537454 0.85 ALOX15 (0.47) PMP22ALOX15BLMKMT2ADPP4
SCHEMBL12497981 0.85 ALOX15 (0.47) PMP22ALOX15BLMKMT2ADPP4
SCHEMBL2695665 0.85 ALOX15 (0.47) PMP22ALOX15BLMKMT2ADPP4
SCHEMBL1537291 0.85 ALOX15 (0.47) PMP22ALOX15BLMKMT2ADPP4
SCHEMBL8637362 0.85 SLC1A1 (0.35) PMP22ALOX15BLMKMT2ADPP4
SCHEMBL1988217 0.85 SLC1A1 (0.35) PMP22ALOX15BLMKMT2ADPP4
SCHEMBL3402553 0.85 GABRP (0.52) PMP22ALOX15BLMKMT2ADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3564376-B1 GENE ENCODING ALANYL-GLUTAMINE DIPEPTIDE BIOSYNTHETIC ENZYME AND APPLICATION THEREOF INNOBIO CORPORATION LTD (CN) 2021-12-15 EP claimed
EP-3880167-A1 METHOD OF PRESERVING CELLS FOR THERAPEUTIC USE Laboratoire Français du Fractionnement et des Biotechnologies (FR) 2021-09-22 EP claimed
EP-3716762-A1 METHOD FOR THE CRYOPRESERVATION OF CELLS FOR THERAPEUTIC PURPOSES Laboratoire Français du Fractionnement et des Biotechnologies (FR) 2020-10-07 EP claimed
WO-2020099571-A1 METHOD OF PRESERVING CELLS FOR THERAPEUTIC USE LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES (FR) 2020-05-22 WO claimed
US-10557854-B2 CA IX—NIR dyes and their uses On Target Laboratories, LLC (US) 2020-02-11 US claimed
WO-2019102172-A1 METHOD FOR THE CRYOPRESERVATION OF CELLS FOR THERAPEUTIC PURPOSES LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES (FR) 2019-05-31 WO claimed
EP-3148563-B1 METHODS AND COMPOSITIONS FOR ENHANCEMENT OF ABILITY TO CONCENTRATE KYOWA HAKKO BIO CO LTD (JP) 2019-05-22 EP claimed
EP-2819685-B1 Use of alanylglutamine for enhancing vision performance KYOWA HAKKO BIO CO LTD (JP) 2018-04-18 EP claimed
EP-2496232-B1 A METHOD TO ENHANCE ENDURANCE KYOWA HAKKO BIO CO LTD (JP) 2016-08-31 EP claimed
EP-2129370-B1 Carbohydrate-based peritoneal dialysis fluid comprising glutamine residue ZYTOPROTEC GMBH (AT) 2012-11-21 EP claimed
EP-1663283-B1 GLUTAMINE FOR USE IN TREATING INJURY UNIV COLORADO (US) 2012-05-23 EP claimed
EP-1940439-B1 REDUCING POST-OPERATIVE ADHESION FORMATION WITH INTRAPERITONEAL GLUTAMINE UNIV SASKATCHEWAN (CA) 2010-10-27 EP claimed
EP-0906333-B1 SUBSTRATES AND INHIBITORS OF PROTEOLYTIC ENZYMES MEDIVIR UK LTD (GB) 2001-07-25 EP claimed
EP-0595345-B1 Process for producing alanylglutamine KYOWA HAKKO KOGYO KK (JP) 2000-01-12 EP claimed
US-11987633-B2 Cross-species-specific single domain bispecific single chain antibody AMGEN RESEARCH (MUNICH) GMBH (DE) 2024-05-21 US disclosed
CN-114345825-B Mask cleaning method, cleaning liquid, cleaning apparatus, and method for manufacturing organic device 大日本印刷株式会社 2023-08-22 CN disclosed
EP-4180458-A1 CROSS-SPECIES-SPECIFIC PSMA X CD3 BISPECIFIC SINGLE CHAIN ANTIBODY Amgen Research (Munich) GmbH (DE) 2023-05-17 EP disclosed
EP-1437966-A1 MEASUREMENT OF PROTEIN SYNTHESIS RATES IN HUMANS AND EXPERIMENTAL SYSTEMS BY USE OF ISOTOPICALLY LABELED WATER The Regents of the University of California (US) 2004-07-21 EP disclosed
WO-2003061479-A1 MEASUREMENT OF PROTEIN SYNTHESIS RATES IN HUMANS AND EXPERIMENTAL SYSTEMS BY USE OF ISOTOPICALLY LABELED WATER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2003-07-31 WO disclosed
WO-2000059925-A1 A PROCESS FOR THE PRODUCTION OF GLUTAMINE DERIVATIVES AND GLUTAMINE CONTAINING MOLECULES THE UNIVERSITY OF VIRGINIA (US) 2000-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10557854-B2 CA IX—NIR dyes and their uses CA9, CA13, CA4 PMP22 4778/4885ALOX15 1706/4885BLM 4551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.